ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 764
2 682
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ASKA Pharmaceutical Holdings Co Ltd
ASKA Pharmaceutical Holdings Co Ltd
Current Portion of Long-Term Debt
ASKA Pharmaceutical Holdings Co Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
|
Current Portion of Long-Term Debt
¥4.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Current Portion of Long-Term Debt
¥624.1B
|
CAGR 3-Years
43%
|
CAGR 5-Years
29%
|
CAGR 10-Years
14%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Current Portion of Long-Term Debt
¥400m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-43%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Current Portion of Long-Term Debt
¥191.2B
|
CAGR 3-Years
57%
|
CAGR 5-Years
20%
|
CAGR 10-Years
9%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Current Portion of Long-Term Debt
¥307.3B
|
CAGR 3-Years
43%
|
CAGR 5-Years
47%
|
CAGR 10-Years
45%
|
|
ASKA Pharmaceutical Holdings Co Ltd
Glance View
ASKA Pharmaceutical Holdings Co., Ltd. engages in the management of its group companies which are involved in the manufacture and sale of pharmaceuticals, quasi-drugs, food, veterinary drugs, feeds, feed additives, and medical devices. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2021-04-01. The firm mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
See Also
What is ASKA Pharmaceutical Holdings Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
4.7B
JPY
Based on the financial report for Mar 31, 2024, ASKA Pharmaceutical Holdings Co Ltd's Current Portion of Long-Term Debt amounts to 4.7B JPY.
What is ASKA Pharmaceutical Holdings Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
9%
Over the last year, the Current Portion of Long-Term Debt growth was 49%. The average annual Current Portion of Long-Term Debt growth rates for ASKA Pharmaceutical Holdings Co Ltd have been 27% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
